Sartorius Stedim Biotech (SSB) and RAUMEDIC announced the signing of a global partnership agreement. This covers arrangements concerning the mutual development of fluid systems and marketing of single-use tubing, which RAUMEDIC produces for and will supply to SSB on a long-term basis. SSB will be combining its designing, manufacturing and validation expertise in single-use systems for biopharmaceutical applications with RAUMEDIC proficiency in the development and manufacture of tubing for medical and biopharmaceutical use. Through this strategic partnership with RAUMEDIC, SSB expects to substantially expand its product and service portfolio in the area of liquid transfer technologies.
The companies will strengthen and develop their existing long-term collaboration and merge their expertise for generating new tubing technologies and validation standards. With a new product line, TuFlux, which will soon be launched, SSB will supply its customers with highly validated polymer and silicone tubing on single-use assemblies as well as stand-alone tubing coils, along with comprehensive validation packages.
According to the agreement, SSV will offer its products backed by RAUMEDIC’s support and assistance in order to develop customized solutions and to provide stronger validation and technical support as well as process improvements.
Jean-Marc Cappia, vice president of fluid management technologies of SSB, acknowledges the agreement as an important milestone in expanding SSB’s product portfolio.
“More than ever, we offer the full capabilities of single-use technologies. For our customers of the biopharmaceutical industry, this partnership will yield a powerful combination of single-use bags, filters, connectors, sensors and tubing systems and services. Our long-term expertise in characterizing extractables in filters and bags will benefit our tubing technology and hence we will be offering more comprehensive validation packages for our single-use solutions,” he explained.
Martin Bayer, CEO of RAUMEDIC, explained the benefits for the biopharmaceutical customers. “This alliance will provide integrated, single-use systems to the global biopharmaceutical industry, which have been developed and harmonized by two strong partners in this area.” he said.
Source: Sartorius Stedim Biotech